Insmed's first quarter 2026 revenue of $306M crushes estimates, driven by a strong BRINSUPRI launch.

Insmed reported first quarter 2026 revenue of $306.0 million and a net loss of $0.76 per share, significantly beating analyst expectations on both the top and bottom line. The results were primarily driven by the strong commercial launch of BRINSUPRI, which offset ARIKAYCE sales that came in below estimates.

Key Highlights

• The newly launched BRINSUPRI (brensocatib) generated revenues of $207.9 million, a 44% sequential increase from the fourth quarter of 2025.
• ARIKAYCE revenues were $98.1 million for the quarter, reflecting a 6% increase year-over-year, driven by international market growth.
• Insmed reiterated its full-year 2026 revenue guidance of at least $1 billion for BRINSUPRI and between $450 million to $470 million for ARIKAYCE.
• The company reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE, which met all primary and key secondary endpoints.